Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Stephanie B WheelerJason RotterAnagha GogateKatherine E Reeder-HayesSarah W DrierDonatus U EkwuemeTemeika L FairleyGabrielle Betty RocqueJustin G TrogdonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In this setting where multiple single-agent chemotherapy options are recommended by clinical guidelines and share similar survival and adverse event trajectories, treatment sequencing approaches that minimize costs early may improve the value of care.